Latest Breaking News On - Clene nanomedicine - Page 8 : vimarsana.com

The Case for Specific Immune Targets in the Diagnosis and Treatment of Neuromyelitis Optica Spectrum Disorder

Monoclonal Antibodies Clinical Trial Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain

/PRNewswire/ -- DelveInsight's 'Monoclonal Antibodies Competitive Landscape – 2023' report provides comprehensive global coverage of available, marketed, and...

Parkinson's Disease Market to Exhibit Growth at a CAGR of 11.2% During the Study Period (2019-2032), Assesses DelveInsight

/PRNewswire/ -- DelveInsight's Parkinson's Disease Market Insights report includes a comprehensive understanding of current treatment practices, Parkinson's...

MS Society awards grant to support clinical trial of CNM-Au8 | Multiple Sclerosis News Today

Clene Nanomedicine has won funding from the National MS Society to continue development of CNM-Au8 for all forms of multiple sclerosis.

DelveInsight Business Research, LLP: Parkinson's Disease Market to Exhibit Growth at a CAGR of 11.2% During the Study Period (2019-2032), Assesses DelveInsight

DelveInsight's analysts estimate that the Parkinson's disease market is expected to show positive growth, mainly attributed to increased prevalence and the anticipated launch of novel therapies

An MS Treatment Worth Its Weight in Gold

How could gold possibly change the course of MS? Drug researchers are working on figuring that out.

Clene Reports First Quarter 2023 Financial Results and Recent Operating Highlights

Clene Reports First Quarter 2023 Financial Results and

ALS biomarker and long-term clinical data expected mid-yearNeurology expert Ben Greenberg, M.D., M.H.S., joined as Head of Medical SALT LAKE CITY, May ...

Global Central Nervous System Partnering 2016-2023: Full Collection of Deals Signed by the World's Pharma and Biotechnology Companies

/PRNewswire/ -- The "Global Central Nervous System Partnering 2016-2023: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's...

ALS and MS Clinical Data from Clene's CNM-Au8® Featured in Multiple Presentations at the 2023 American Academy of Neurology Annual Meeting

SALT LAKE CITY, April 25, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) a...